Sophia Colantonio

Sophia Colantonio

Auto-generated profile, based on publicly available information

Sophia Colantonio

Division of Dermatology, Department of Medicine, University of Ottawa, ON, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
ASAlison Spurr
Alison Spurr
NHNardin Hanna
Nardin Hanna
SCSophia Colantonio
Sophia Colantonio
Microblading is a novel method of semi-permanent makeup, which has achieved popularity in the last few years. We present the case of a patient who developed cutaneous sarcoidosis after microblading of her eyebrows. A 45-year-old female presented with a 6-month history of pruritic erythematous granulomatous plaques on bilateral eyebrows corresponding to the site of microblading 1.5 years prior. A tissue biopsy was preformed which was consistent with cutaneous sarcoidosis. An extensive work-up including assessment by respirology, rheumatology, and ophthalmology did not reveal any evidence of systemic sarcoidosis. The patient was treated with intralesional triamcinolone injections and tacrolimus ointment twice daily, with complete resolution. To our knowledge, this is the first case of cutaneous sarcoidosis associated with microblading in the literature. Dermatologists should be aware of popular and novel cosmetic procedures and the potential complications that arise from these interventions.

20 March 2023 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
LMLinda Mardiros
Linda Mardiros
FMFarhan Mahmood
Farhan Mahmood
SCSophia Colantonio
Sophia Colantonio
RBReetesh Bose
Reetesh Bose
Background: Dermatology for diverse skin types is a globally growing area of medicine, but the inclusion of skin of color dermatology has not yet been formally included across all Canadian undergraduate medical education curricula. There is also a paucity of representation of diverse skin types in most medical textbooks, research, and clinical trials. Objectives: The main objective was to develop a concise, Skin of Colour Dermatoses Self-Learning Module (SOCSLM) that could be implemented at an undergraduate medical education level. The secondary objective was to analyze participant responses to improve and add to learning module content. Methods: From March to May 2022, second-year medical students at the University of Ottawa completed pre- and post-SOCSLM questionnaires which were available in French and English through their online student learning portals. The pre-test consisted of five multiple choice questions relating to images of dermatoses seen in diverse skin types. The post-test repeated the same five questions, rearranged, with an additional five new ones, and responses were analyzed. Results: Twenty-five participants completed the surveys, and twenty responses were included. Percent correct answers increased between pre- and post-test, 51% vs 87%. In the post-test, questions repeated from the pre-test had a mean score of 95% while the new post-test questions had a mean score of 80%. Interest in dermatology did not have an impact on correct response rates. Conclusions: Skin of color dermatology self-learning modules may be an effective way to integrate skin of color dermatology into undergraduate medical curricula.

9 September 2021 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
PDF file
SOSelam Ogbalidet
Selam Ogbalidet
AFAlexandra Finstad
Alexandra Finstad
MBMina Boshra
Mina Boshra
FMFarhan Mahmood
Farhan Mahmood
VLVictoria Lanoe
Victoria Lanoe
SCSophia Colantonio
Sophia Colantonio

7 August 2017 in Canadian Medical Association Journal
Verified
Journal Article
Open access
PDF file
SCSophia Colantonio
Sophia Colantonio
CKCarly Kirshen
Carly Kirshen
A healthy 28-year-old woman with a history of herpes labialis and atopic dermatitis was seen by the dermatology department after three days of substantially pruritic and edematous erythematous lip plaques with vesicles ([Figure 1A][1]), which caused difficulty in eating and drinking. She also had a

1 January 2025 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
OYOrhan Yilmaz
Orhan Yilmaz
RBReetesh Bose
Reetesh Bose
SCSophia Colantonio
Sophia Colantonio
Morbihan’s disease is a rare form of facial lymphedema often associated with chronic rosacea and other skin diseases such as acne. It presents as indurated erythematous plaques in the upper face, which can be challenging to treat. We report a 69-year-old male of Asian background with a 4-year history of facial swelling and redness, unresponsive to prior treatments. After a clinical diagnosis of Morbihan’s disease, the patient was treated with oral isotretinoin 10 mg daily, leading to an 80% reduction in symptoms after 9 months. Mild side effects, including cheilitis and xerosis, were well managed. This case highlights low-dose isotretinoin’s potential as a therapeutic option for Morbihan’s disease. Previous studies have demonstrated the efficacy of treating Morbihan’s disease with isotretinoin at high doses between 40 and 80 mg po daily for 12–24 months.

24 May 2025 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
BMBarbara Marzario
Barbara Marzario
DCDaniela Cino
Daniela Cino
SCSophia Colantonio
Sophia Colantonio
This case report describes, to our knowledge, the first known successful treatment of airborne allergic contact dermatitis to sesquiterpene lactone with upadacitinib in an adult patient. Recurrent summertime photodistributed eczematous eruptions should raise suspicion for airborne allergic contact dermatitis to sesquiterpene lactone, and positive patch test results to sesquiterpene lactone and Compositae in these patients should be considered highly relevant. In addition to allergen avoidance, treatment with systemic Janus kinase inhibitors can induce allergic contact dermatitis remission. Our patient did not respond to allergen avoidance or topical corticosteroids; however, he achieved almost complete resolution of his allergic contact dermatitis with a 6-week course of upadacitinib, a Janus kinase 1 inhibitor.